newsfilter
← Latest News
GlobeNewswire·

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Vaxxinity's next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized vaccine platforms: